Table 1.
Baseline Risk Factorsδ in Women with SLE (Cases) and Controls from the Study of Lupus Vascular and Bone Longterm Endpoints (2002-present), Chicago, IL
| Cases (N=149) | Controls (N=124) | P-value* | |
|---|---|---|---|
|
|
|||
| Traditional CV Risk Factors | |||
| Age (years, mean ±SD) | 43.1 ± 9.9 | 46.3 ± 10.3 | 0.01 |
| Hypertension (N (%)) | 74 (49.7) | 31 (25.0) | <0.001 |
| Waist Circumference (cm) | 88.1 ± 17.1 | 89.5 ± 17.3 | 0.52 |
| Total Cholesterol/HDL Ratio | 3.7 ± 1.4 | 3.5 ± 1.0 | 0.13 |
| GFR (ml/min) | 84.0 ± 22.2 | 80.8 ± 18.4 | 0.20 |
| Diabetes (N (%))$ | 13 (8.7) | 4 (3.2) | 0.08 |
| Smoker (N (%)) | 14 (9.4) | 11 (8.9) | 1.00 |
| Lipoprotein(a) (mg/dl) | 47.3 ± 45.5 | 37.8 ± 37.4 | 0.06 |
| Fibrinogen (mg/dl) | 326.9 ± 103.3 | 322.0 ± 87.7 | 0.67 |
| CRP (mg/dl) | 4 ± 8.3 | 3.1 ± 4.9 | 0.25 |
| Homocysteine (mg/dl) | 10.9 ± 3.7 | 8.7 ± 3.2 | <0.001 |
| Framingham Risk (%)& | 4.1 ± 4.0 | 4.6 ± 4.7 | 0.41 |
| Race (%) | |||
| Caucasian | 63.1 | 67.7 | 0.45 |
| African-American | 26.2 | 23.4 | 0.67 |
| Asian | 6.0 | 2.4 | 0.24 |
| Hispanic | 4.7 | 6.5 | 0.60 |
| SLE-Related Factors | |||
| SLEDAI-2K | 3.8 ± 3.4 | - | - |
| ACR/SLICC-DI** | 1.5 ± 1.7 | - | - |
| Anti-dsDNA (by Crithidia) | 76.8 ± 166.1 | - | - |
| Positive Anti-dsDNA(N (%)) | 69 (46.3) | - | - |
| Current corticosteroid dose (mg) | 4.4 ± 7.8 | - | - |
| Cumulative corticosteroid dose (mg) | 102.7 ± 112.0 | ||
| Complement component 3 (C3) (mg/dl) | 99.7 ± 28.4 | - | - |
| Complement component 4 (C4) (mg/dl) | 19.6 ± 8.9 | - | - |
| Disease Duration (y) | 12.2 ± 9.0 | - | - |
| Current Medication Use | |||
| Hydroxychloroquine (N (%)) | 109 (73.2) | - | - |
| Corticosteroids (N (%)) | 57 (38.3) | - | - |
| Immunosuppressants (N(%))μ | 53 (35.6) | - | - |
| Estrogen (N (%)) | 13 (8.7) | 9 (7.3) | 0.82 |
| Aspirin (N (%)) | 26 (17.4) | 9 (7.3) | 0.02 |
| Statin (N (%)) | 11 (7.4) | 7 (5.6) | 0.63 |
(mean±SD)
two-sided t-test used for continuous variables, and Fisher’s exact test for proportions
fasting glucose ≥ 126 or on diabetes medication or self-reported diabetes
10-year general cardiovascular disease risk
Excluding coronary artery bypass grafting, myocardial infarction, stroke, and angina
mycophenolate mofetil, azathioprine, methotrexate
SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000
Mod ACR/SLICC-DI: American College of Rheumatology/Systemic Lupus International Collaborative Clinics Damage Index, excluding coronary artery bypass grafting, myocardial infarction, stroke, and angina.